OMG! Cream for Female Arousal

Forward-looking statements, in some cases, can be identified by terms

• Viagra cream is considered experimental by many health authorities.
• It is not approved by the FDA for medical use.
• Efficacy evidence mainly comes from anecdotal reports.
• Risks associated include allergic reactions and skin burns.
• It can be part of a broader treatment plan for ED.
• Safe disposal of unused cream is necessary to prevent misuse.
• The cream may interact with other medications, demanding caution.
• Clinical trials are needed to confirm safety and efficiency.
• Patients should report adverse effects promptly.
• Distribution channels are often unregulated, so caution is advised.

such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”

• The effectiveness of Viagra cream depends on skin absorption.
• It is sometimes promoted as a natural alternative.
• Possible benefits include reduced frequency of side effects.
• Scientific evidence supporting its use is limited.
• Users should be wary of false advertising claims.
• Some formulations may contain unsafe or unregulated ingredients.
• Proper use involves cleaning the application area thoroughly.
• The cream should be applied as per product instructions.
• Do not exceed recommended dosage to avoid irritation.
• Keep out of reach of children and pets.

“could,” “plan,” “potential,” “seek,” “should,” “would,” “project,” “target,” “explore” “objective,” “on

Menopause Care Made Easy

Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website. Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. track,” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to,

statements relating to plans and timing for commercial availability of DARE to

• Viagra cream is a topical treatment designed for erectile dysfunction.
• It contains the active ingredient sildenafil.
• Applied directly to the skin for quick absorption.
• Typically used before sexual activity for increased blood flow.
• Often marketed as an alternative to oral tablets.
• May have fewer systemic side effects than pills.
• Application areas usually include the inner thigh or genitals.
• Effectiveness can vary depending on individual response.
• Needs to be applied about 15-30 minutes prior to sex.
• Not suitable for people allergic to sildenafil or similar drugs.

PLAY™ Sildenafil Cream in states in the U.S., production of the compounded drug product in accordance with cGMP requirements, the ability of the product

How the Cream Works: Arousal, Nitric Oxide, and Touch

DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to women. DARE to PLAY™ uses sildenafil, the same active ingredient found in Viagra®, to improve genital blood flow. Applied topically, it’s designed for use as needed, to enhance the body’s natural arousal response without systemic effects, providing women with a new, evidence-based tool to take charge of their sexual health. “When Viagra was approved in 1998, it revolutionized sexual medicine for men.

Vaginal Itching and Menopause: Causes and Relief

But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “We believe DARE to PLAY™ represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.” Existing products promoted for arousal lean heavily on marketing language, consumer reviews, and lifestyle branding without real evidence. DARE to PLAY™ is the first and only topical formulation of sildenafil developed specifically for women and backed by: Toxicology studies covering oral, anal, vaginal, and reproductive health; Multiple clinical trials in women, including a randomized placebo-controlled study with 200 women and their sexual partners; and Published, peer-reviewed research in medical journals such as The Green Journal, the official publication of the American College of Obstetrics and Gynecology (ACOG) and the Journal of Sexual Medicine, the official publication of the International Society for the Study of Women’s Sexual Health (ISSWSH). “As more women speak openly about their sexual health, the need for research-backed solutions has never been greater,” said Dr. Irwin Goldstein, Director of San Diego Sexual Medicine and a founder of ISSWSH.

Formulated to work within 30 minutes

“Daré’s commitment to both clinical integrity and timely access ensures women who need it don’t have to wait to benefit from this innovation.” While continuing activities necessary to seek U.S. Food and Drug Administration (FDA) approval of its proprietary sildenafil cream formulation in the future, Daré Bioscience is making DARE to PLAY™ available as a Section 503B compounded product, manufactured in an outsourcing facility subject to FDA inspection and under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency. Compounded drug products are not FDA approved. The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. DARE to PLAY™ can now be prescribed for pre-order by licensed healthcare providers for prescription fulfillment in these states: CT, FL, IN, MO, NH, NJ, OR, PA, RI, and UT, and will ship within 45 days of order placement during the pre-order phase. to enhance genital arousal response in women without systemic effects, the market

• Viagra cream might offer more control over dosing.
• It is often marketed to men seeking non-pill options.
• Some users report increased confidence with topical application.
• The cream is designed for convenience and discreetness.
• It may be combined with lubricants for comfort.
• Skin sensitivity varies, so patch testing is advised.
• The onset of action can be faster than oral forms.
• Interaction with other topical products is unknown.
• Not a cure for sexual dysfunction—only temporary enhancement.
• Consult a healthcare provider about underlying causes of ED.

opportunity for the product, its market position, its impact in women’s sexual health, and its ability to gain market acceptance, and Daré’s plans to

Advice & Empathy: A Personal Note to Women Considering the Cream

“We have this scientific evidence that sildenafil as an active ingredient can work if only it were designed and formulated specifically with women in mind and that's really where we came into the equation," Sabrina Martucci Johnson, president and CEO of Dare Bioscience was quoted as saying by New York Post. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades." The Southern California company stated that it was continuing to seek necessary approvals for the product from the US Food and Drug Administration (FDA), adding that its effectiveness was backed by toxicology studies, multiple clinical trials and peer-reviewed research. During the trials, the Dare to Play cream increased libido as well as orgasms with no potential side effects compared to a placebo cream. It was also tested in oral sex situations. "Phase 2b trial included 200 premenopausal women experiencing symptoms of female sexual interest/arousal disorder, such as reduced genital sensation and frustration during intimacy," the company said.

Let's do it.

After 12 weeks, women who used the cream reported an increase in arousal as well as key areas of sexual function, including desire and orgasm. Johnson said the new cream represents a "long overdue correction" that allows women an option to reconnect with their own bodies, with science finally recognising their needs as well. As for why a pill akin to those used by men was not developed, Johnson said a female pill would require a lot of sildenafil. She added that the option was "just not practical" as it would require much higher doses than what men generally need. Residents of Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island and Utah can pre-order the cream already.

Potential side effects

Track Latest News Live on NDTV.com and get news updates from India and around the world Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY™ Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. seek FDA approval of its sildenafil cream formulation, pending additional development activities.

THE BIG “O” (OVERVIEW)

DARE to PLAY™ prescriptions are being accepted through the DARE Health Hub, managed by Medvantx. DARE to PLAY™ will be available in other 25 mg viagra states throughout December and early 2026. Visit for more information on DARE to PLAY™, including how to access a prescription and to sign up for an alert on when it is available in your state. An estimated 20 million women in the United States experience challenges related to genital arousal, yet there are no FDA-approved therapeutics to address this need. The availability of DARE to PLAY™ through a cGMP 503B facility provides this large, underserved community of women access to a product uniquely supported by clinical evidence and scientific rigor.

Cell Signal

References to Section 503B, 503B, 503B compounding, 503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance with Section 503B. Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline.

Can men use scream cream?

With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor – randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements. To learn more about Daré’s mission to deliver differentiated therapies for women and its innovation pipeline, please visit Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website ( SEC filings, press releases, public conference calls and webcasts.